---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-067579"
form_type: "8-K"
ticker: "MIST"
cik: "0001408443"
company_name: "Milestone Pharmaceuticals Inc."
filed_at: "2025-07-14T23:59:59+00:00"
generated_at: "2026-05-18T06:37:40.975239+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Milestone Pharmaceuticals prices $52.5M public offering of common shares and warrants

## Summary
- Priced $52.5M offering of 31.5M common shares + Series A and B warrants at $1.50/unit; 3.5M pre-funded warrants at $1.499/unit.
- Net proceeds expected ~$48.7M after underwriting commissions and expenses.
- Series A warrants exercisable at $1.50 for 1 year; Series B at $1.875 for 5 years, with mandatory exercise trigger at $3.50 VWAP.
- Proceeds to fund etripamil clinical development and commercial launch for paroxysmal supraventricular tachycardia (PSVT).
- Offering led by TD Cowen, Piper Sandler, Wells Fargo; expected to close July 14, 2025.

## SEC filing metadata
- accession: 0001104659-25-067579
- form_type: 8-K
- ticker: MIST
- cik: 0001408443
- company_name: Milestone Pharmaceuticals Inc.
- filed_at: 2025-07-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1408443/000110465925067579/0001104659-25-067579-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1408443/000110465925067579/tm2520713d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-067579
- JSON: https://secwatch.observer/filing/0001104659-25-067579.json
- Plain text: https://secwatch.observer/filing/0001104659-25-067579.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.